QPS Acquires Bioserve

QPS, LLC has acquired of a majority stake in Bioserve Clinical Research. Bioserve, a full service phase I CRO headquartered in Hyderabad, India, will be known as QPS-Bioserve India. QPS is a global CRO supporting drug discovery and development, with expertise in preclinical DMPK/toxicology, bioanalytical, translational medicine, and early- and late-stage clinical research.

Bioserve has a 92-bed clinical unit for conducting phase I studies and a bioanalytical lab equipped with multiple LC/MS/MS systems for small molecule bioanalysis. In the past six years, it has conducted more than 500 studies, with numerous product approvals, and has been inspected by the USFDA, UK MHRA, WHO and Indian DCGI.

“This new partnership further expands QPS’ global range of linearly integrated services,” said Ben Chien, Ph.D., chairman, president and chief executive officer of QPS. “With access to Bioserve’s additional resources, our customers will have the heightened benefits of a third more phase I beds, bringing our total to 400, greater bioanalytical capacity, and access to another facility, located in India, with a reputation for outstanding performance and a record of timely approvals. Furthermore, current customers will be reassured to learn that Mr. Suneil Reddy will remain as managing director.”